The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity - PubMed (original) (raw)

. 2003 May 1;63(9):2046-51.

Affiliations

PMID: 12727818

The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity

Li Hua Wang et al. Cancer Res. 2003.

Abstract

Breast cancer, the most common malignancy in women, has been demonstrated to be associated with the steroid hormone estrogen and its receptor (ER), a ligand-activated transcription factor. Therefore, we developed a phosphorothiolate cis-element decoy against the estrogen response element (ERE decoy) to target disruption of ER DNA binding and transcriptional activity. Here, we showed that the ERE decoy potently ablated the 17beta-estrogen-inducible cell proliferation and induced apoptosis of human breast carcinoma cells by functionally affecting expression of c-fos gene and AP-1 luciferase gene reporter activity. Specificity of the decoy was demonstrated by its ability to directly block ER binding to a cis-element probe and transactivation. Moreover, the decoy failed to inhibit ER-mediated mitogen-activated protein kinase signaling pathways and cell growth of ER-negative breast cancer cells. Taken together, these data suggest that estrogen-mediated cell growth of breast cancer cells can be preferentially restricted via targeted disruption of ER at the level of DNA binding by a novel and specific decoy strategy applied to steroid nuclear receptors.

PubMed Disclaimer

Cited by

Nuclear Receptors, Ligands and the Mammalian B Cell.
Jones BG, Penkert RR, Surman SL, Sealy RE, Hurwitz JL. Jones BG, et al. Int J Mol Sci. 2020 Jul 15;21(14):4997. doi: 10.3390/ijms21144997. Int J Mol Sci. 2020. PMID: 32679815 Free PMC article. Review.
From Influenza Virus Infections to Lupus: Synchronous Estrogen Receptor α and RNA Polymerase II Binding Within the Immunoglobulin Heavy Chain Locus.
Jones BG, Sealy RE, Penkert RR, Surman SL, Birshtein BK, Xu B, Neale G, Maul RW, Gearhart PJ, Hurwitz JL. Jones BG, et al. Viral Immunol. 2020 May;33(4):307-315. doi: 10.1089/vim.2019.0144. Epub 2020 Feb 27. Viral Immunol. 2020. PMID: 32105583 Free PMC article.
Matters of life and death: How estrogen and estrogen receptor binding to the immunoglobulin heavy chain locus may influence outcomes of infection, allergy, and autoimmune disease.
Jones BG, Penkert RR, Surman SL, Sealy RE, Pelletier S, Xu B, Neale G, Maul RW, Gearhart PJ, Hurwitz JL. Jones BG, et al. Cell Immunol. 2019 Dec;346:103996. doi: 10.1016/j.cellimm.2019.103996. Epub 2019 Oct 25. Cell Immunol. 2019. PMID: 31703914 Free PMC article. Review.
Molecular mechanism of estrogen-estrogen receptor signaling.
Yaşar P, Ayaz G, User SD, Güpür G, Muyan M. Yaşar P, et al. Reprod Med Biol. 2016 Dec 5;16(1):4-20. doi: 10.1002/rmb2.12006. eCollection 2017 Jan. Reprod Med Biol. 2016. PMID: 29259445 Free PMC article. Review.
Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.
Nott SL, Huang Y, Kalkanoglu A, Harper K, Chen M, Paoni SF, Fenton BM, Muyan M. Nott SL, et al. Mol Med. 2010 Jan-Feb;16(1-2):10-8. doi: 10.2119/molmed.2009.00107. Epub 2009 Nov 17. Mol Med. 2010. PMID: 19946606 Free PMC article.

The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity - PubMed (original) (raw)